Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Central Pharmaceuticals's Enterprise Value is BDT1,644.94 Mil.
Central Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0.01 Mil. Therefore, Central Pharmaceuticals's EV-to-FCF for today is 182,771.33.
The historical rank and industry rank for Central Pharmaceuticals's EV-to-FCF or its related term are showing as below:
DHA:CENTRALPHL'
s EV-to-FCF Range Over the Past 10 Years
Min: -223521.27 Med: 57.9 Max: 177447.01
Current: 170791.22
During the past 13 years, the highest EV-to-FCF of Central Pharmaceuticals was 177447.01. The lowest was -223521.27. And the median was 57.90.
DHA:CENTRALPHL's EV-to-FCF is ranked worse than 100% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs DHA:CENTRALPHL: 170791.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Central Pharmaceuticals (DHA:CENTRALPHL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Central Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Central Pharmaceuticals's share price for today is BDT11.50.
Central Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-0.166.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:CENTRALPHL vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Central Pharmaceuticals's EV-to-FCF falls into.
Central Pharmaceuticals's current Enterprise Value is BDT1,644.94 Mil.
Central Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals (DHA:CENTRALPHL) has a EV-to-FCF of 182,771.33 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Central Pharmaceuticals and its competitors. This is 315567% above median its historical median of 57.90. According to the industry distribution chart, Central Pharmaceuticals ranks #569 out of 569 companies in the Drug Manufacturers industry.
Is Central Pharmaceuticals' EV-to-FCF too high?
Central Pharmaceuticals' current EV-to-FCF of 182,771.33 is 315567% above median its 10-year median of 57.90. The Drug Manufacturers industry median EV-to-FCF is 21.60. Central Pharmaceuticals' value of 182,771.33 is 846063.6% above this industry median. Based on the distribution chart, Central Pharmaceuticals ranks #569 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Central Pharmaceuticals ranks #569 out of 569 companies for EV-to-FCF. This places Central Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 21.60. Central Pharmaceuticals' value of 182,771.33 is 846063.6% above this benchmark. While the company's 10-year median is 57.90 vs. the industry median of 21.60, Central Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Pharmaceuticals's current EV-to-FCF of 182,771.33 is 846063.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Central Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceuticals's current EV-to-FCF is 182,771.33, which is 315567% above median its own 10-year median of 57.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.07, compared to a current price of BDT11.50 — trading 4.7% below its estimated fair value. The current EV-to-FCF is 182,771.33, which is 315567% above median its 10-year median of 57.90 and 846063.6% above the Drug Manufacturers industry median of 21.60. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current EV-to-FCF is 182,771.33 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT11.50 is trading 4.7% below its estimated GF Value™ of BDT12.07.
GuruFocus considers Central Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:CENTRALPHL:
EV-to-FCF: 182,771.33 (315567% above median its 10-year median of 57.90)
GF Value™: BDT12.07 vs. price of BDT11.50 (4.7% below fair value)
Industry Position: 846063.6% above the Drug Manufacturers median (#569 of 569)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score
Get the complete analysis for DHA:CENTRALPHL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
